L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:20333 CAPLUS Full-text
DN 140:93926
TI Preparation of sulfonylaminovalerolactams as factor Xa inhibitors
IN Smallheer, Joanne M.; Pinto, Donald J.; Wang, Shuaige; Qiao, Jennifer X.; Han, Wei; Hu, Zilun
PA USA
SO U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004006062	A1	20040108	US 2003-429461	20030505
WO 2004041776	A2	20040521	WO 2003-US14142	20030505
WO 2004041776	A3	20040910		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-378313P P 20020506
OS MARPAT 140:93926
GI



I



II

AB The title compds. I [G = Ph, pyridyl, pyrrolyl, etc.; G1 = H, alkyl, acyl, (substituted) amino, etc.; A = (substituted) Ph, carbocyclic, heterocyclyl; B = lactam, heterocyclyl, etc.; n = 0-2] were prepared I can be used as inhibitors of trypsin-like serine proteases, specifically factor Xa. Thus, II is prepared from 1-[4-(3-amino-2-oxopiperidin-1-yl)-3- fluorophenyl]-piperidin-2-one (preparation given) and 6-chloronaphthalene-2- sulfonyl chloride. Pharmaceutical compds. containing I are described.

IT **641612-58-0P 641612-59-1P 641612-60-4P**
641612-61-5P 641612-62-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of sulfonylaminovalerolactams as factor Xa inhibitors)

RN 641612-58-0 CAPLUS
CN Acetamide, 2-[[(6-chloro-2-naphthalenyl)sulfonyl][1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]-N-methyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 641612-59-1 CAPLUS
CN Piperazine, 1-[[[(6-chloro-2-naphthalenyl)sulfonyl][1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 641612-60-4 CAPLUS
CN Morpholine, 4-[[[(6-chloro-2-naphthalenyl)sulfonyl][1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 641612-61-5 CAPLUS
CN Acetamide, 2-[[(6-chloro-2-naphthalenyl)sulfonyl][1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]-N-(2-

hydroxyethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 641612-62-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



IT **477739-35-8P 477739-36-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(preparation of sulfonylaminovalerolactams as factor Xa inhibitors)
RN 477739-35-8 CAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-36-9 CAPLUS
CN Acetamide, 2-[[(6-chloro-2-naphthalenyl)sulfonyl][1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]-N-[2-(dimethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)


O
Me
CH2
C
N
CH2
CH2
NMe2
O
S
N
Cl
O
O
N
F
O
S
O
Me

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:203407 CAPLUS Full-text
DN 138:238181
TI Preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C
IN Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PA Japan Tobacco Inc., Japan
SO U.S. Pat. Appl. Publ., 406 pp., Cont.-in-part of Appl. No. PCT/JP00/09181. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003050320	A1	20030313	US 2001-939374	20010824
	US 6770666	B2	20040803		
	WO 2001047883	A1	20010705	WO 2000-JP9181	20001222
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2001247550	A2	20010911	JP 2000-391904	20001225
	US 2004097438	A1	20040520	US 2003-615329	20030708
PRAI	JP 1999-369008	A	19991227		
	WO 2000-JP9181	A2	20001222		
	JP 2000-391904	A	20001225		
	JP 2001-193786	A	20010626		
	US 2001-939374	A3	20010824		

OS MARPAT 138:238181
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2, G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, S, CR7, etc.; R1-R4 = H, NO2, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = Ph, cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, CN, etc.; R7 = H, alkyl] are prepared and formulated. Compds. I showed HCV polymerase inhibitory activity (data given). E.g., a multi-step synthesis of II.HCl, starting from 2-bromo-5-nitrotoluene and Me 2-(2-fluoro-4-hydroxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylate, was given.

IT **480461-56-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C)
RN 480461-56-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-(2-oxo-1-piperidinyl)[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:5773 CAPLUS Full-text
DN 138:66657
TI Fused cyclic compounds and medicinal use thereof
IN Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PA Japan Tobacco Inc., Japan
SO PCT Int. Appl., 603 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003000254	A1	20030103	WO 2002-JP6405	20020626
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2003212846	A2	20030730	JP 2002-185241	20020625
	BR 2002005684	A	20030617	BR 2002-5684	20020626
	EP 1400241	A1	20040324	EP 2002-743728	20020626
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004082635	A1	20040429	US 2003-344997	20030218
	NO 2003000832	A	20030422	NO 2003-832	20030221
PRAI	JP 2001-193786	A	20010626		
	JP 2001-351537	A	20011116		
	WO 2002-JP6405	W	20020626		

OS MARPAT 138:66657
GI



I

AB Fused cyclic compds. represented by the following general formula [I] or pharmaceutically acceptable salts thereof and remedies for hepatitis C containing these compds.: I wherein each symbol is as defined in the description. Because of having an effect against hepatitis C virus (HVC) based on an HCV polymerase inhibitory effect, these compds. are useful as remedies or preventives for hepatitis C.

IT **480461-56-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(fused cyclic compds. as hepatitis C virus polymerase inhibitors and antiviral agents)
RN 480461-56-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-(2-oxo-1-piperidinyl)[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-,

monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

App'S

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:928243 CAPLUS Full-text
DN 138:14012
TI Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
IN Jacobson, Irina C.; Wexler, Ruth R.; Nakajima, Suanne; Quan, Mimi L.; Wang, Shuaige; Smallheer, Joanne M.; Qiao, Jennifer
PA Bristol-Myers Squibb Pharma. Co., USA
SO U.S. Pat. Appl. Publ., 114 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002183324	A1	20021205	US 2001-3125	20011029
	US 6710058	B2	20040323		
	WO 2002102380	A1	20021227	WO 2001-US51621	20011030
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1337251	A1	20030827	EP 2001-274110	20011030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004132718	A1	20040708	US 2003-730170	20031208
PRAI	US 2000-246107P	P	20001106		
	US 2001-313552P	P	20010820		
	US 2001-3125	A3	20011029		
	WO 2001-US51621	W	20011030		

OS MARPAT 138:14012
GI



I

AB Monocyclic or bicyclic carbocycles and heterocycles and their pharmaceutically acceptable salts are useful as inhibitors of factor Xa in the treatment of thromboembolic diseases. Thus, 1-(4-bromo-2-fluorophenyl)-3-hydroxy-2-piperidinone was treated with 3-NCC6H4OH and the resulting piperidinyloxybenzonitrile was coupled with 2-MeSC6H4B(OH)2 to give the biphenyl I. Numerous compds. of the invention possessed Ki values of ≤ 10 μM in assays with human factor Xa.

IT **477738-34-4P 477738-43-5P 477738-46-8P**
477738-62-8P 477738-72-0P 477738-78-6P
477738-93-5P 477739-33-6P 477739-35-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of biphenylylpiperidinones as factor Xa inhibitors)

RN 477738-34-4 CAPLUS

CN Benzonitrile, 3-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-43-5 CAPLUS

CN Benzamide, 3-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-46-8 CAPLUS

CN Benzamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-62-8 CAPLUS

CN Benzoic acid, 2-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 477738-72-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-78-6 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-93-5 CAPLUS
CN Benzenesulfonamide, 3-chloro-4-fluoro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-33-6 CAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 477739-35-8 CAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



IT **477738-35-5P 477738-36-6P 477738-37-7P**
477738-38-8P 477738-39-9P 477738-40-2P
477738-42-4P 477738-44-6P 477738-45-7P
477738-47-9P 477738-48-0P 477738-49-1P
477738-50-4P 477738-53-7P 477738-54-8P
477738-56-0P 477738-58-2P 477738-59-3P
477738-60-6P 477738-61-7P 477738-63-9P
477738-64-0P 477738-65-1P 477738-66-2P

477738-67-3P 477738-68-4P 477738-69-5P
477738-70-8P 477738-71-9P 477738-73-1P
477738-74-2P 477738-75-3P 477738-76-4P
477738-77-5P 477738-79-7P 477738-80-0P
477738-81-1P 477738-82-2P 477738-83-3P
477738-84-4P 477738-85-5P 477738-86-6P
477738-87-7P 477738-88-8P 477738-89-9P
477738-90-2P 477738-91-3P 477738-92-4P
477738-94-6P 477738-95-7P 477738-96-8P
477738-97-9P 477738-98-0P 477738-99-1P
477739-00-7P 477739-01-8P 477739-02-9P
477739-03-0P 477739-04-1P 477739-05-2P
477739-06-3P 477739-07-4P 477739-08-5P
477739-09-6P 477739-10-9P 477739-11-0P
477739-12-1P 477739-13-2P 477739-27-8P
477739-28-9P 477739-31-4P 477739-32-5P
477739-34-7P 477739-36-9P 477739-37-0P
477739-38-1P 477739-39-2P 477739-40-5P
477739-41-6P 477739-42-7P 477739-43-8P
477739-44-9P 477739-45-0P 477739-46-1P
477740-12-8P 477740-13-9P 477740-14-0P
477740-15-1P 477740-16-2P 477740-17-3P
477740-18-4P 477740-19-5P 477740-20-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of biphenylylpiperidinones as factor Xa inhibitors)

RN 477738-35-5 CAPLUS
CN Benzenecarboximidamide, 3-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-36-6 CAPLUS
CN Benzenecarboximidamide, 4-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-37-7 CAPLUS
CN Benzonitrile, 3-[[1-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-38-8 CAPLUS
CN Benzenecarboximidamide, 3-[[1-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-

biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-39-9 CAPLUS
CN Benzenecarboximidamide, 3-[[1-[2'-[(dimethylamino)methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 477738-40-2 CAPLUS
CN Benzenecarboximidamide, 3-[[1-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 477738-42-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-44-6 CAPLUS
CN Benzamide, 3,4-dichloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-45-7 CAPLUS
CN Benzamide, 4-fluoro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-47-9 CAPLUS
CN Benzamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 477738-48-0 CAPLUS
CN Benzamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 477738-49-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-50-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-53-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-6-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 477738-54-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-chloro-, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl ester (9CI) (CA INDEX NAME)



RN 477738-56-0 CAPLUS
CN Benzoic acid, 4-methoxy-, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl ester (9CI) (CA INDEX NAME)



RN 477738-58-2 CAPLUS
CN Benzaldehyde, 2-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]-5-methoxy- (9CI) (CA INDEX NAME)



RN 477738-59-3 CAPLUS
CN 2-Piperidinone, 3-[(5-chloro-2-pyridinyl)amino]-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477738-60-6 CAPLUS
CN 2-Piperidinone, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(4-methoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 477738-61-7 CAPLUS
CN 2-Piperidinone, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 477738-63-9 CAPLUS

CN 2-Piperidinone, 3-[3-(aminomethyl)phenoxy]-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477738-64-0 CAPLUS
CN 2-Piperidinone, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-[4-methoxy-2-[(phenylamino)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 477738-65-1 CAPLUS
CN Benzamide, 2-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]oxy]-5-methoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 477738-66-2 CAPLUS
CN Benzamide, 3-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 477738-67-3 CAPLUS
CN Benzamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477738-68-4 CAPLUS
CN 1H-Indole-5-carboxamide, N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-69-5 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-70-8 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-71-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-73-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-74-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-amino-N-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-75-3 CAPLUS
CN 2-Piperidinone, 3-[[(4-chlorophenyl)methyl]amino]-1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477738-76-4 CAPLUS
CN Benzenecarboximidamide, 3-[[[1-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 477738-77-5 CAPLUS
CN Benzenecarboximidamide, 3-[[[1-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl](phenylmethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 477738-79-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-80-0 CAPLUS
CN 2-Naphthalenesulfonamide, 7-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-81-1 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-82-2 CAPLUS
CN 2-Thiophenesulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-5-(3-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 477738-83-3 CAPLUS
CN Benzenesulfonamide, 4-fluoro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-84-4 CAPLUS
CN Benzenesulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 477738-85-5 CAPLUS
CN Benzenesulfonamide, 4-ethyl-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-86-6 CAPLUS
CN Benzenesulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 477738-87-7 CAPLUS
CN 3-Pyridinesulfonamide, 5-bromo-6-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-88-8 CAPLUS
CN 2-Thiophenesulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 477738-89-9 CAPLUS
CN Benzenesulfonamide, 3,4-difluoro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-90-2 CAPLUS
CN Benzenesulfonamide, 3-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-91-3 CAPLUS
CN 2-Thiophenesulfonamide, 3,5-dichloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-92-4 CAPLUS
CN Benzenesulfonamide, 4-cyano-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-94-6 CAPLUS
CN 1H-Imidazole-4-sulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 477738-95-7 CAPLUS
CN Benzenesulfonamide, 2,5-dichloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-96-8 CAPLUS
CN Benzenesulfonamide, 3,5-dichloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-97-9 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[2'-[(diethylamino)methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-98-0 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[2-oxo-1-[2'-(1-pyrrolidinylmethyl)[1,1'-biphenyl]-4-yl]-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477738-99-1 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[2'-[(3-hydroxy-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-00-7 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[2'-[(4-hydroxy-1-piperidinyl)methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-01-8 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[2'-[[(2-hydroxyethyl)methylamino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-(9CI) (CA INDEX NAME)



RN 477739-02-9 CAPLUS
CN 1,2-Benzisoxazole-5-sulfonamide, 3-amino-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-03-0 CAPLUS
CN 2-Piperidinone, 3-[(3-amino-1,2-benzisoxazol-5-yl)amino]-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477739-04-1 CAPLUS
CN Benzenecarboximidamide, 2-fluoro-5-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 477739-05-2 CAPLUS

CN 2-Piperidinone, 3-[[3-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)phenyl]amino]-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477739-06-3 CAPLUS

CN Benzenesulfonamide, 3-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-07-4 CAPLUS

CN 2-Piperidinone, 3-[3-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)phenoxy]-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477739-08-5 CAPLUS

CN Benzamide, 3-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-09-6 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477739-10-9 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 477739-11-0 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-ethyl-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-12-1 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 477739-13-2 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 477739-27-8 CAPLUS
CN Benzamide, 4-chloro-N-[1-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-28-9 CAPLUS
CN 3-Piperidineacetic acid, 3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-1-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 477739-31-4 CAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 477739-32-5 CAPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 477739-34-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-

(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477739-36-9 CAPLUS
CN Acetamide, 2-[[(6-chloro-2-naphthalenyl)sulfonyl][1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]-N-[2-(dimethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 477739-37-0 CAPLUS
CN Acetamide, 2-[[(6-chloro-2-naphthalenyl)sulfonyl][1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 477739-38-1 CAPLUS
CN Acetamide, 2-[[(6-chloro-2-naphthalenyl)sulfonyl][1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 477739-39-2 CAPLUS
CN Benzenesulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-40-5 CAPLUS
CN 3-Pyridinesulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-41-6 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 477739-42-7 CAPLUS
CN 3-Quinolinesulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-43-8 CAPLUS
CN 6-Quinolinesulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-44-9 CAPLUS
CN 6-Quinoxalinesulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-45-0 CAPLUS
CN 3-Pyridinesulfonamide, 6-amino-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-46-1 CAPLUS
CN 2H-Indazole-6-sulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477740-12-8 CAPLUS
CN Benzamide, 3-chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-13-9 CAPLUS
CN Benzenecarboximidamide, 3-[[[1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl](phenylmethyl)amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 477740-14-0 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[2'-[(diethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-15-1 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-(1-pyrrolidinylmethyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-16-2 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-[(3-hydroxy-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-17-3 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-[(4-hydroxy-1-piperidinyl)methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-18-4 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-[[(2-hydroxyethyl)methylamino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 477740-19-5 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-[3-fluoro-2'-[(4-hydroxy-1-piperidinyl)methyl][1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-3-methyl-(9CI) (CA INDEX NAME)



RN 477740-20-8 CAPLUS
CN 1H-Indazole-6-sulfonamide, N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



IT **471908-93-7P 477739-49-4P 477739-50-7P**
477739-56-3P 477739-58-5P 477739-61-0P
477739-62-1P 477739-63-2P 477739-64-3P
477739-65-4P 477740-01-5P 477740-21-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(preparation of biphenylylpiperidinones as factor Xa inhibitors)

RN 471908-93-7 CAPLUS

CN 2-Piperidinone, 3-bromo-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477739-49-4 CAPLUS

CN 2-Piperidinone, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-hydroxy- (9CI) (CA INDEX NAME)



RN 477739-50-7 CAPLUS

CN 2-Piperidinone, 3-amino-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 477739-56-3 CAPLUS

CN Benzenecarboximidamide, 3-[[[1-[2'-[[(1,1-dimethylethyl)amino]sulfonyl][1, 1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 477739-58-5 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[3-[[(3-cyanophenyl)sulfonyl](phenylmethyl)amino]-2-oxo-1-piperidinyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 477739-61-0 CAPLUS
CN 2-Thiophenesulfonamide, 5-chloro-N-[1-(2'-formyl[1,1'-biphenyl]-4-yl)-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-62-1 CAPLUS
CN Benzenesulfonamide, 3-cyano-4-fluoro-N-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477739-63-2 CAPLUS
CN Benzonitrile, 2-fluoro-5-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 477739-64-3 CAPLUS
CN Carbamic acid, (3-amino-1,2-benzisoxazol-5-yl)[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 477739-65-4 CAPLUS
CN Benzonitrile, 3-[[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 477740-01-5 CAPLUS
CN Benzamide, 4-chloro-N-[1-[2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 477740-21-9 CAPLUS
CN Carbamic acid, (3-cyano-4-fluorophenyl)[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:793361 CAPLUS Full-text
DN 137:310810
TI Preparation of indole and other fused heterocyclic inhibitors of factor Xa useful for treating/preventing thromboembolic disorders
IN Jacobson, Irina C.; Quan, Mimi L.; Wexler, Ruth R.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080853	A2	20021017	WO 2002-US10891	20020408
	WO 2002080853	A3	20030227		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003087909	A1	20030508	US 2002-118102	20020408
	US 6790845	B2	20040914		
PRAI	US 2001-282438P	P	20010409		

OS MARPAT 137:310810
GI



I



II

AB This invention relates generally to a novel class of fused heterocyclic compds. (shown as I and II; e.g. 1-[[1-(3-fluoro-2'-methylsulfonyl)[1,1'- biphenyl]-4-yl]-2-oxo-3-piperidinyl]-1H-indole-6-carbonitrile) or pharmaceutically acceptable salt forms thereof, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compns. containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders. Some compds. of this invention were evaluated and found to exhibit a Ki of ≤10 μM, thereby confirming the utility of the compds. of the present invention as effective thrombin inhibitors. Although the methods of preparation are not claimed, .apprx.15 example prepns. are included. In I and II, ring D, including the two atoms of ring E to which it is attached, is a 5-6 membered nonarom. ring consisting of C atoms, 0-1 double bonds, and 0-2 heteroatoms N, O, and S(O)p, and ring D is substituted with 0-2 R1, provided that when ring D is unsubstituted, it consists of at least one heteroatom; alternatively,

ring D, including the two atoms of ring E to which it is attached, is a 5-6 membered aromatic system consisting of C atoms and 0-2 heteroatoms N, O, and S(O)p, and ring D is substituted with 0-2 R1, provided that when ring D is unsubstituted, it consists of at least one heteroatom. E is selected from Ph, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and is substituted with 0-1 R1; alternatively, ring D is absent and ring E is selected from Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, thienyl and triazolyl, and ring E is substituted with 0-2 Ra; Ra is selected from H, C1-4 alkyl, F, Cl, Br, I, OH, OCH3, OCH2CH3, OCH(CH3)2, OCH2CH2CH3, CN, C(:NR8)NR7R9, NHC(:NR8)NR7R9, NR8CH(:NR7), C(O)NR7R8, (CR8R9)tNR7R8, SH, SCH3, SCH2CH3, SCHMe2, SCH2CH2CH3, S(O)R3b, S(O)2R3a, S(O)2NR2R2a, and OCF3; alternatively, two Ras combine to form methylenedioxy or ethylenedioxy. Alternatively, ring D is absent and ring E is selected from Ph, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and thienyl, and ring E is substituted with 1 R and with a 5-6 membered aromatic heterocycle consisting of: C atoms and 1-4 heteroatoms N, O, and S(O)p substituted with 0-1 carbonyl groups and 0-2 R1. Ring F completes a 5-7 membered heterocycle consisting of C atoms, 1-3 heteroatoms N, NH, O, and -S(O)p-, 0-2 addnl. double bonds, and 0-2 carbonyl groups, provided that other than a O-O, O-S, or S-S bond is present in the ring and ring F is substituted with 0-1 R4c. Ring G completes a 5-7 membered nonarom. heterocycle consisting of C atoms, 1-3 heteroatoms N, NZ, O, and S(O)p, 0-2 double bonds, and 0-3 carbonyl groups, and ring G is substituted with 0-2 R1a, provided that other than a O-O, O-S, or S-S bond is present in ring G. Z is selected from H, S(O)2NHR3, C(O)R3, C(O)NHR3, C(O)OR3f, S(O)R3f, S(O)2R3f, C1-6 alkyl substituted with 0-2 R1a; C2-6 alkenyl substituted with 0-2 R1a; C2-6 alkynyl substituted with 0-2 R1a; -(C0-4 alkyl)-C3-10-carbocycle substituted with 0-3 R1a; -(C0-4 alkyl)-5-12 membered-heterocycle substituted with 0-3 R1a. G1 is selected from C, CH, and N; G2 is selected from CH, CH2, C(O), O, S(O)p, N, and NH; G3 is selected from C, CH, and N; A is selected from C3-10 carbocycle substituted with 0-2 R4, and 5-12 membered heterocycle consisting of C atoms and from 1-4 heteroatoms N, O, and S and substituted with 0-2 R4; B is selected from: Y, X-Y, (CH2)0-2C(O)NR2R2a, (CH2)0-2NR2R2a, C(:NR2)NR2R2a, and NR2C(:NR2)NR2R2a, provided that G3 and B are attached to different atoms on A. X is selected from -(CR2R2a)1-4-, -CR2(CR2R2b)(CH2)t-, -C(O)-, -C(:NR1c)-, -CR2(NR2R2a)-, -CR2(OR2)-, -CR2(SR2)-, -C(O)CR2R2a-, -CR2R2aC(O), -S-, -S(O)-, -S(O)2-, -SCR2R2a-, -S(O)CR2R2a-, -S(O)2CR2R2a-, -CR2R2aS-, -CR2R2aS(O)-, -CR2R2aS(O)2-, -S(O)2NR2-, -NR2S(O)2-, -NR2S(O)2CR2R2a-, -CR2R2aS(O)2NR2-, -NR2S(O)2NR2-, -C(O)NR2-, -NR2C(O)-, -C(O)NR2CR2R2a-, -NR2C(O)CR2R2a-, -CR2R2aC(O)NR2-, -CR2R2aNR2C(O)-, -NR2C(O)O-, -OC(O)NR2-, -NR2C(O)NR2-, -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, O, -CR2R2aO-, and -OCR2R2a-. Y is selected from -(CH2)rNR2R2a; C3-10 carbocycle substituted with 0-2 R4a; and 5-10 membered heterocycle consisting of C atoms and from 1-4 heteroatoms N, O, and S and substituted with 0-2 R4a; provided that X-Y do not form a N-N, O-N, or S-N bond; V is selected from C, CH, and N; U is a bond or is selected from CHR3b, C(O), O, S(O)p, NR3b, C(O)NR3, NR3C(O), C(O)CH2, CH2C(O), S(O)pNR3, NR3S(O)p, OCH2, CH2O, NR3bCH2, and CH2NR3b; provided that when ring D is absent, U is other than a bond; W is a bond or is selected from CHR3b, C(O), O, S(O)p, NR3b, C(O)NR3, NR3C(O), C(O)CH2, CH2C(O), S(O)pNR3, NR3S(O)p, OCH2, CH2O, NR3bCH2, and CH2NR3b; provided that when ring D is absent, W is a bond. Variables in I and II not defined above are defined in the claims.

IT **471908-90-4P**, 1-[1-[2'-[(Dimethylamino)methyl]-3-fluoro[1,1'-

biphenyl]-4-yl]-2-oxo-3-piperidinyl]-6-indoline carbonitrile
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of indole and other fused heterocyclic inhibitors of factor Xa useful for treating/preventing thromboembolic disorders)

RN 471908-90-4 CAPLUS

CN 1H-Indole-6-carbonitrile, 1-[1-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



IT **471908-92-6P**, 1-[3-Fluoro-2'-(methylsulfanyl)[1,1'-biphenyl]-4-yl]-3-hydroxy-2-piperidinone **471908-93-7P**, 3-Bromo-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-piperidinone **471908-94-8P**, 3-Bromo-1-[3-fluoro-2'-(methylsulfanyl)[1,1'-biphenyl]-4-yl]-2-piperidinone **471908-98-2P**, 1-[1-[(3-Fluoro-2'-methylsulfanyl)[1,1'-biphenyl]-4-yl]-2-oxopiperidin-3-yl]-1H-indazole-6-carbonitrile **471908-99-3P**, 1-[1-[(3-Fluoro-2'-methanesulfonyl)[1,1'-biphenyl]-4-yl]-2-oxopiperidin-3-yl]-1H-indazole-6-carbonitrile **471909-01-0P**, 3-[1-[(3-Fluoro-2'-methylsulfanyl)[1,1'-biphenyl]-4-yl]-2-oxopiperidin-3-yl]-3H-benzimidazole-5-carbonitrile **471909-02-1P**, 1-[1-[(3-Fluoro-2'-methylsulfanyl)[1,1'-biphenyl]-4-yl]-2-oxopiperidin-3-yl]-1H-benzimidazole-5-carbonitrile **471909-03-2P**, 3-[1-[(3-Fluoro-2'-methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxopiperidin-3-yl]-3H-benzimidazole-5-carbonitrile **471909-05-4P**, 1-[1-[(3-Fluoro-2'-methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxopiperidin-3-yl]-1H-benzimidazole-5-carbonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(intermediate; preparation of indole and other fused heterocyclic inhibitors of factor Xa useful for treating/preventing thromboembolic disorders)

RN 471908-92-6 CAPLUS

CN 2-Piperidinone, 1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-3-hydroxy-(9CI) (CA INDEX NAME)



RN 471908-93-7 CAPLUS

CN 2-Piperidinone, 3-bromo-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 471908-94-8 CAPLUS
CN 2-Piperidinone, 3-bromo-1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-(9CI) (CA INDEX NAME)



RN 471908-98-2 CAPLUS
CN 1H-Indazole-6-carbonitrile, 1-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 471908-99-3 CAPLUS
CN 1H-Indazole-6-carbonitrile, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 471909-01-0 CAPLUS
CN 1H-Benzimidazole-6-carbonitrile, 1-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 471909-02-1 CAPLUS
CN 1H-Benzimidazole-5-carbonitrile, 1-[1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 471909-03-2 CAPLUS
CN 1H-Benzimidazole-6-carbonitrile, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 471909-05-4 CAPLUS
CN 1H-Benzimidazole-5-carbonitrile, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



IT **471908-88-0P**, 1-[1-[3-Fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-1H-indole-6-carbonitrile **471909-07-6P** **471909-09-8P**, 1-[1-[3-Fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxopiperidin-3-yl]-5-methoxy-1,3-dihydrobenzimidazol-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indole and other fused heterocyclic inhibitors of factor Xa useful for treating/preventing thromboembolic disorders)

RN 471908-88-0 CAPLUS
CN 1H-Indole-6-carbonitrile, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 471909-07-6 CAPLUS
CN 2-Piperidinone, 3-(3,4-dihydro-6-methoxy-1(2H)-quinolinyl)-1-[3-fluoro-2'-(methylthio)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 471909-09-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-1,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)



IT **471908-85-7P**, 1-[1-[3-Fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-1H-indole-6-carboximidamide **471908-89-1P**, 1-[1-[2'-[(Dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-6-indoline carboximidamide **471908-91-5P**, Ethyl 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-5-methoxy-1H-indole-2-carboxylate **471908-95-9P**, 1-[3-Fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(5-methoxy-1H-indol-1-yl)-2-piperidinone **471908-96-0P**, 3-[1-[3-Fluoro-2'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-2-oxopiperidin-3-yl]-6-methoxy-3H-benzoxazol-2-one **471908-97-1P**, 1-[1-[3-Fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-1H-indazole-6-carboximidamide **471909-00-9P**, 3-[1-[3-Fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-3H-benzimidazole-5-carboximidamide **471909-04-3P**, 1-[1-[(3-Fluoro-2'-methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-1H-benzimidazole-5-carboximidamide **471909-06-5P**, 1-[1-[3-Fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxopiperidin-3-yl]-5-methoxy-1H-indole-2,3-dione **471909-08-7P** **471909-10-1P**, 1-[1-(3-Fluoro-2'-methylsulfonyl[1,1'-biphenyl]-4-yl)-2-oxopiperidin-3-yl]-3-isopropyl-5-methoxy-1,3-dihydrobenzimidazol-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole and other fused heterocyclic inhibitors of factor Xa useful for treating/preventing thromboembolic disorders)

RN 471908-85-7 CAPLUS

CN 1H-Indole-6-carboximidamide, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 471908-89-1 CAPLUS
CN 1H-Indole-6-carboximidamide, 1-[1-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 471908-91-5 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 471908-95-9 CAPLUS
CN 2-Piperidinone, 1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(5-

methoxy-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 471908-96-0 CAPLUS
CN 2(3H)-Benzoxazolone, 3-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-
yl]-2-oxo-3-piperidinyl]-6-methoxy- (9CI) (CA INDEX NAME)



RN 471908-97-1 CAPLUS
CN 1H-Indazole-6-carboximidamide, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 471909-00-9 CAPLUS
CN 1H-Benzimidazole-6-carboximidamide, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 471909-04-3 CAPLUS
CN 1H-Benzimidazole-5-carboximidamide, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]- (9CI) (CA INDEX NAME)



RN 471909-06-5 CAPLUS
CN 1H-Indole-2,3-dione, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-piperidinyl]-5-methoxy- (9CI) (CA INDEX NAME)



RN 471909-08-7 CAPLUS
CN 2-Piperidinone, 3-(3,4-dihydro-6-methoxy-1(2H)-quinolinyl)-1-[3-fluoro-2'-(methylsulfinyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 471909-10-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-
yl]-2-oxo-3-piperidinyl]-1,3-dihydro-5-methoxy-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:640672 CAPLUS Full-text
DN 127:307374
TI Spirocyclic piperidine derivatives useful as 5-HT1B receptor antagonists
IN Gaster, Laramie Mary; Ham, Peter; King, Francis David; Wyman, Paul Adrian
PA Smithkline Beecham PLC, UK; Gaster, Laramie Mary; Ham, Peter; King, Francis David; Wyman, Paul Adrian
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9734901	A1	19970925	WO 1997-EP1404	19970319
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9702329	A	19980918	ZA 1997-2329	19970318
	CA 2250016	AA	19970925	CA 1997-2250016	19970319
	AU 9721581	A1	19971010	AU 1997-21581	19970319
	EP 888358	A1	19990107	EP 1997-914271	19970319
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2000507240	T2	20000613	JP 1997-533157	19970319
	US 6100272	A	20000808	US 1998-142988	19980918
PRAI	GB 1996-5883	A	19960320		
	WO 1997-EP1404	W	19970319		

OS MARPAT 127:307374
GI



I



II

AB Novel piperidine derivs. I [R = NR1COR2 or (un)substituted heterocyclyl; R1 = H, alkyl; R2 = H, alkyl, (un)substituted aryl; or R1R3 = (CH2)2-4; R4, R5 = H, halo, alkoxy, acyloxy, OH, NO2, CF3, cyano, CO2H or derivs.,

(un)substituted alkyl or NH2, etc; B = O, S; D = N, C, CH; R6 = H, alkyl; R7 = H, alkyl, alkoxy, halo; or R6R7 = (CH2)2-4 or (CH2)0-3J with optional alkyl substituent(s), where J = O, S, CH:CH, CH:N, :CHO, :CHS, or :CHNH with optional alkyl substituents; R8 = H, alkyl, cycloalkyl, alkenyl, or alkylcycloalkyl; R9, R10 = H, alkyl; E = O, CH2, NH, or SO0-2 with optional alkyl substituents; G = CO or (CH2)1-3 with optional alkyl substituents; X, Y = CR9R10; m = 1-3] and their salts and N-oxides, processes for their preparation, pharmaceutical compns. containing them, and their use as medicaments are disclosed. The compds. are selective 5-HT1B receptor antagonists, useful for treatment of a variety of CNS and other disorders. Examples include prepns. of 33 compds. I and their salts, and approx. 70 intermediates. For instance, amidation of the amine intermediate 1'-methyl-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'- piperidine] with the corresponding Me ester in the presence of AlMe3 in PhMe gave 61% title compound II. In an assay using CHO cells expressing 5-HT1B receptors, II had a pKi value > 8.0.

IT **197450-06-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(intermediate; preparation of spiro[furoindolepiperidine] derivs. and analogs as 5-HT1B receptor antagonists)

RN 197450-06-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 2'-methyl-4'-(2-oxo-1-piperidinyl)-, methyl ester (9CI) (CA INDEX NAME)



IT **197449-61-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of spiro[furoindolepiperidine] derivs. and analogs as 5-HT1B receptor antagonists)

RN 197449-61-9 CAPLUS

CN Spiro[2H-furo[2,3-f]indole-3(5H),4'-piperidine], 6,7-dihydro-1'-methyl-5-[[2'-methyl-4'-(2-oxo-1-piperidinyl)[1,1'-biphenyl]-4-yl]carbonyl]-(9CI)(CA INDEX NAME)


N
O
Me
Me
N
C
O
N
O

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1987:440519 CAPLUS Full-text
DN 107:40519
TI Manufacture of p-phenylene bis(glutaric acid) and its linear polyimides
IN Teshirogi, Takuma
PA Daicel Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61251636	A2	19861108	JP 1985-91232	19850430
	JP 07080813	B4	19950830		
	JP 06025414	A2	19940201	JP 1993-113321	19930514
PRAI	JP 1985-91232		19850430		

GI



III

AB Title compound (I) is prepared from p-phenylenebis(α-cyanoacrylic acid) (II) C1-4 alkyl esters and cyclic diesters III (R2, R3 = C1-4 alkyl). Title polyimides with good thermal stability are prepared by condensation of I dianhydride and aromatic diamines. Thus, 64.8 g II diethyl ester was dispersed in MeOH, treated with NaOH solution of 63.4 g Meldrum's acid over 2 h, stirred for 10 h, and heated with Ac2O to form I dianhydride, which was stirred with diaminodiphenyl ether for 24 h, and heated at 120-200° for 3 h, then at 200° in vacuo for 10 h, to obtain a transparent yellowish film showing good thermal stability (10% weight loss at 405° when heated in air at 5°/min).

IT **107040-00-6P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(manufacture of, thermally stable and transparent)

RN 107040-00-6 CAPLUS
CN Poly[(2,6-dioxo-1,4-piperidinediyl)-1,4-phenylene(2,6-dioxo-4,1-piperidinediyl)(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)] (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1987:102756 CAPLUS Full-text
DN 106:102756
TI Aliphatic polyimides from phenylene bis(succinic anhydride) and bis(glutaric anhydride)
AU Teshirogi, Takuma
CS Macromol. Res. Lab., Yamagata Univ., Yonezawa, 992, Japan
SO Journal of Polymer Science, Part A: Polymer Chemistry (1987), 25(1), 31-6 CODEN: JPACEC; ISSN: 0887-624X
DT Journal
LA English
AB m- And p-derivs. of phenylene bis(succinic anhydride) and bis(glutaric anhydride) were obtained from 1,3- [77104-43-9] and 1,4-bis(β-cyano- β-carbethoxyvinyl)benzene [47375-13-3] with KCN or Meldrum's acid followed by hydrolysis with concentrated HCl and dehydration with Ac2O. Aliphatic polyimides were prepared from these anhydrides with 6 aromatic diamines through thermal ring closure of polyamic acids obtained by solution polymerization in AcNMe2, and thermal stability of these polyimides was examined by thermogravimetric anal.
IT **107040-00-6P 107065-76-9P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and thermal stability of)
RN 107040-00-6 CAPLUS
CN Poly[(2,6-dioxo-1,4-piperidinediyl)-1,4-phenylene(2,6-dioxo-4,1-piperidinediyl)(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)] (9CI) (CA INDEX NAME)



RN 107065-76-9 CAPLUS
CN Poly[(2,6-dioxo-1,4-piperidinediyl)-1,3-phenylene(2,6-dioxo-4,1-piperidinediyl)(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1977:171880 CAPLUS Full-text
DN 86:171880
TI Synthesis and properties of poly(pyromellitimide-glutarimide) copolymers
AU Yang, Chin-Ping
CS Tatung Inst. Technol., Taipei, Taiwan
SO Datong Xuebao (1974), 4, 21-39
CODEN: TTHPCI; ISSN: 0379-7309
DT Journal
LA English
AB Polyimides with weight loss <10% at 400° in air were obtained in 80-90% yields by ring-opening solution condensation of N,N'-diglutaric anhydride pyromellitimide (I) [53022-19-8] with diamines to give polyimide-amic acids, which were dehydrated in the presence of Ac2O and a catalyst. I was prepared by reaction of glutamic acid [56-86-0] with pyromellitic anhydride [89-32-7] at 30-60° in DMF. I was condensed with aromatic diamines and NH2(CH2)6NH2 in solution at room temperature in 6-10 h to form 85-98% of the polyimide-amic acids. The acids produced a stable viscous solution which did not gel on prolonged storage at room temperature The polyimides were obtained by heating a solution of the acid in AcNMe2 at 100° in the presence of Ac2O and pyridine. The structure of the polymers was confirmed using model compds., and their solubility and heat-resistance was evaluated. The polyimides gave clear, tough films when cast from polar solvents.
IT **53022-66-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)(heat-resistant, preparation of)
RN 53022-66-5 CAPLUS
CN Poly[(5,7-dihydro-1,3,5,7-tetraoxobenzo[1,2-c:4,5-c']dipyrrole-2,6(1H,3H)-diyl)[(3S)-2,6-dioxo-3,1-piperidinediyl][1,1'-biphenyl]-4,4'-diyl[(3S)-2,6-dioxo-1,3-piperidinediyl]] (9CI) (CA INDEX NAME)



IT **53022-56-3**
RL: USES (Uses)
(model compds., for diglutaric anhydride pyromellitimide-based polyimide)
RN 53022-56-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(2,6-dioxo-1,3-piperidinediyl)]bis-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1974:569897 CAPLUS Full-text
DN 81:169897
TI Synthesis and properties of copolypyromellitimide-glutarimides
AU Yang, C. P.
CS Tatung Inst. Technol., Taipei, Taiwan
SO Datong Xuebao (1974), 4, 21-39
CODEN: TTHPCI; ISSN: 0379-7309
DT Journal
LA English
AB Polyimides (7) containing glutarimide- and pyromellitimide units in the main chain were prepared by ring opening of N,N'-diglutaric anhydride pyromellitimide (I) [53022-19-8] with diamines in solution to give polyamic acids, which were converted by ring closure to the desired polyimides. I was prepared by reaction of glutamic acid [56-86-0] with pyromellitic anhydride [89-32-7]. The polyamic acids formed from I and diamines were very stable in solution; no gelation was observed during long storage at room temperature Conversion of the polyamic acids to polyimides was effected with dehydrating agents and catalysts such as pyridine. The polyimides gave clear films with excellent heat resistance. The kinetics, mechanisms, ir spectra, solubilities and thermal anal. properties of the polymers were studied. In an example, I-p,p'-diaminodiphenyl ether polymer (II, SRU) [53109-44-7] was obtained in 92% yield and had sp. viscosity 0.26 (0.5 g/dl., Me2SO, 30.deg.) compared to 0.69 (0.5 g/dl., Me2NAc, 30.deg.) for its resp. polyamic acid [53149-10-3].
IT **53022-56-3**
RL: USES (Uses)(model compound, for polyimide preparation)
RN 53022-56-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(2,6-dioxo-1,3-piperidinediyl)]bis-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





IT **53022-66-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 53022-66-5 CAPLUS
CN Poly[(5,7-dihydro-1,3,5,7-tetraoxobenzo[1,2-c:4,5-c']dipyrrole-2,6(1H,3H)-diyl)[(3S)-2,6-dioxo-3,1-piperidinediyl][1,1'-biphenyl]-4,4'-diyl[(3S)-2,6-dioxo-1,3-piperidinediyl]] (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1974:404289 CAPLUS Full-text
DN 81:4289
TI Syntheses and properties of new aromatic-aliphatic copolyimides
AU Iwakura, Yoshia; Yang, Chin-Ping; Uno, Keikichi
CS Fac. Eng., Univ. Tokyo, Tokyo, Japan
SO Makromolekulare Chemie (1974), 175(1), 137-59
CODEN: MACEAK; ISSN: 0025-116X
DT Journal
LA English
AB Aromatic-aliphatic copolyimides containing both pyromellitimide and succinimide or glutarimide rings in the main chain were prepared by a conventional 2-step poly(amic acid) formation and cyclodehydration reaction of 2,2'-(pyromellitic diimide)-N,N'-bis(succinic anhydride) (I, m=1) [51774-96-0] or 2,2'-(pyromellitic diimide)-N,N'-bis(glutaric anhydride) (I, m=2) [51774-97-1] with primary aromatic or aliphatic diamines. The poly(amic acids) did not gel during storage in polar solvents at room temperature The copolyimides gave tough, clear, flexible films from DMSO, and had good heat and oxidation resistance. The I were prepared from pyromellitic dianhydride [89-32-7] and glutamic acid [56-86-0] or aspartic acid [56-84-8].
IT **52605-05-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52605-05-7 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(2,6-dioxo-3,1-piperidinediyl)]bis- (9CI) (CA INDEX NAME)



IT **52455-98-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of heat-resistant, with improved solubility)
RN 52455-98-8 CAPLUS
CN Poly[(5,7-dihydro-1,3,5,7-tetraoxobenzo[1,2-c:4,5-c']dipyrrole-2,6(1H,3H)-diyl)(2,6-dioxo-3,1-piperidinediyl)[1,1'-biphenyl]-4,4'-diyl(2,6-dioxo-1,3-piperidinediyl)] (9CI) (CA INDEX NAME)



=> d l1; d his; log y
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 18:17:17 ON 09 NOV 2004)

FILE 'REGISTRY' ENTERED AT 18:17:24 ON 09 NOV 2004
L1 STRUCTURE UPLOADED
L2 6 S L1
L3 152 S L1 FUL

FILE 'CAPLUS' ENTERED AT 18:17:45 ON 09 NOV 2004
L4 11 S L3

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	52.80	208.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.70	-7.70

STN INTERNATIONAL LOGOFF AT 18:18:32 ON 09 NOV 2004